Sandeep N. Athalye

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

Christopher Wynne, Mario Altendorfer, Ivo Sonderegger et al. · Expert Opinion on Investigational Drugs · 2016 · 59 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

Thomas Blevins, Abhijit Barve, Yaron Raiter et al. · Diabetes Obesity and Metabolism · 2019 · 35 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

Suresh Kumar, Rosemarie de Souza, Milind Nadkar et al. · Expert Opinion on Biological Therapy · 2021 · 33 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

Thomas Blevins, Abhijit Barve, Bin Sun et al. · Diabetes Obesity and Metabolism · 2018 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Willem Hettema, Christopher Wynne, Benjamin Lang et al. · Expert Opinion on Investigational Drugs · 2017 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17